Cervical Cancer
Cervical cancer is a malignant tumor that occurs in the cervical region of the female reproductive system. The main cause of cervical cancer is human papillomavirus (HPV) infection, especially high-risk types of HPV, such as HPV types 16 and 18. Other associated risk factors include smoking, multiple sexual partners, early sexual initiation, multiple pregnancies and births, and immune deficiency. The clinical presentation of cervical cancer varies with the progression of the disease and may be asymptomatic in the early stages, but as the disease progresses, symptoms such as contact bleeding and abnormal vaginal bleeding may occur.
In terms of cervical cancer treatment, according to the stage of the cancer and the specific conditions of the patients, commonly used treatments include surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. Surgery is usually applied to early stage cervical cancer, while radiotherapy and chemotherapy are commonly used in the treatment of middle and late stage cervical cancer. Targeted therapy and immunotherapy are emerging treatments in recent years, which are mainly used in the treatment of recurrent or advanced cervical cancer.
The current research and development of cervical cancer drugs are mostly focused on the following directions:
- Immune checkpoint inhibitors: PD-1/L1 inhibitors such as pabolizumab (PD-1 inhibitor) have been approved by the U.S. FDA for the treatment of recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. In addition, pabolizumab in combination with chemotherapy is also approved for the first-line treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1.
- Antibody-drug couplers (ADCs): Tisotumab Vedotin (TV) is the first ADC approved for the treatment of cervical cancer in patients with recurrent or metastatic cervical cancer whose disease has progressed during or after chemotherapy.The Phase III innovaTV301 trial of TV for the second-line treatment of cervical cancer showed that, compared to conventional chemotherapy, the TV significantly reduced the risk of death and improved patients' overall survival (OS).
- Bispecific Antibody: Cadonilimab (AK104), a bispecific antibody targeting PD-1 and CTLA-4 independently developed by a domestic company, has been applied for marketing for the treatment of recurrent or metastatic cervical cancer and has been granted priority review.
Cervical Cancer Drug Targets
Cervical Cancer Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
HFACS assay shows that Human TIGIT can bind to 293F cell overexpressing human CD155.
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC50 is 12.32-15.74 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized TFRC (CSB-MP3648HU)at 2μg/mL can bind Human TF，the EC50 is 58.72-77.84 ng/mL.
